Lifeboat Foundation

For nearly his entire life, Dr. Stuart Hameroff has been fascinated with the bedeviling question of consciousness. But instead of studying neurology or another field commonly associated with the inner workings of the brain, it was Hameroff’s familiarity with anesthetics, a family of drugs that famously induces the opposite of consciousness, that fueled his curiosity.

“I thought about neurology, psychology, and neurosurgery, but none of those… eemed to be dealing with the problem of consciousness,” says Hameroff, a now-retired professor of anesthesiology from the University of Arizona. Hameroff recalls a particularly eye-opening moment when he first arrived at the university and met the chairman of the anesthesia department. “He says ‘hey, if you want to understand consciousness, figure out how anesthesia works because we don’t have a clue.’”

Hameroff’s work in anesthesia showed that unconsciousness occurred due to some effect on microtubules and wondered if perhaps these structures somehow played a role in forming consciousness. So instead of using the neuron, or the brain’s nerve cells, as the “base unit” of consciousness, Hameroff’s ideas delved deeper and looked at the billions of individual tubulins inside microtubules themselves. He quickly became obsessed.

Researchers at University of California San Diego have developed and tested a new software package, called Spatial Modeling Algorithms for Reactions and Transport (SMART), that can realistically simulate cell-signaling networks—the complex systems of molecular interactions that allow cells to respond to diverse cues from their environment.

Cell-signaling networks involve many distinct steps and are also greatly influenced by the complex, three-dimensional shapes of cells and subcellular components, making them difficult to simulate with existing tools. SMART offers a solution to this problem, which could help accelerate research in fields across the life sciences, such as systems biology, pharmacology and biomedical engineering.

The researchers successfully tested the new software in biological systems at several different scales, from cell signaling in response to adhesive cues, to calcium release events in subcellular regions of neurons and cardiac muscle cells, to the production of ATP (the energy currency in cells) within a detailed representation of a single mitochondrion.

The Russian Ministry of Health has announced that it has developed a vaccine against cancer that will be distributed to Russian patients for free from early 2025.

According to TASS, the Russian state-owned news agency, Andrey Kaprin—the General Director of the Radiology Medical Research Center of the Russian Ministry of Health—recently announcement the development on Russian radio.

The vaccine will apparently be used to treat cancer patients, rather than given to the general public to prevent cancer—and it will be personalized to each patient.

Caltech researchers have developed a new method to map the positions of hundreds of DNA-associated proteins within cell nuclei all at the same time. The method, called ChIP–DIP (Chromatin ImmunoPrecipitation Done In Parallel), is a versatile tool for understanding the inner workings of the nucleus during different contexts, such as disease or development.

The research was conducted in the laboratory of Mitchell Guttman, professor of biology, and is described in a paper that appears in the journal Nature Genetics.

Nearly all cells in the human body contain the same DNA, which encodes the blueprint for creating every cell type in the body and directing their activities. Despite having the same genetic material, different cell types express unique sets of proteins, allowing for the various cells to perform their specialized functions and to adapt to conditions within their environments. This is possible because of careful regulation within the nucleus of each cell and involves thousands of regulatory proteins that localize to precise places in the nucleus.

Using dual lasers and an advanced gas injection system, researchers at the Berkeley Lab Laser Accelerator Center (BELLA) accelerated a high-quality electron beam to 10 billion electronvolts (10 GeV) over a distance of just 30 centimeters.

Laser-plasma accelerators have the potential to dramatically shrink the size and cost of particle accelerators, benefiting fields such as high-energy physics, medicine, and materials science. Key achievements from BELLA’s recent experiment include:

A team of Children’s Medical Research Institute (CMRI) scientists has identified a new method for producing a therapeutic product that has the potential to improve the treatment of cancer.

The work by Associate Professor Leszek Lisowski and his Translational Vectorology Research Unit is published in the journal Molecular Therapy.

Chimeric antigen receptor (CAR) T cells, also known as CAR T therapies, are a relatively new form of treatment showing very exciting results for several types of cancer. While initially validated for the treatment of B cell malignancies, especially acute lymphoblastic leukemia (ALL), the technology has also shown promise for other cancer types, including solid tumors.

Through its commitment to international nuclear nonproliferation — a mission focused on limiting the spread of nuclear weapons and sensitive technology while working to promote peaceful use of nuclear science and technology — the United States maintains a constant vigilance aimed at reducing the threat of nuclear and radiological terrorism worldwide.

With extensive research into both basic and applied uranium science, as well as internationally deployed operational solutions, the Department of Energy’s Oak Ridge National Laboratory is uniquely positioned to contribute its comprehensive capabilities toward advancing the U.S. nonproliferation mission.

In 1943, seemingly overnight, ORNL emerged from a rural Tennessee valley as the site of the world’s first continuously operating nuclear reactor, in support of U.S. efforts to end World War II. ORNL’s mission soon shifted into peacetime applications, harnessing nuclear science for medical treatments, power generation and breakthroughs in materials, biological and computational sciences.

AstroCrete uses a protein found in plasma as a binder. No, really.

Gene-editing technologies for cancer and blood disorders are maturing a little more than a year after the first CRISPR drug was approved.